ATE446104T1 - Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor - Google Patents

Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor

Info

Publication number
ATE446104T1
ATE446104T1 AT02702211T AT02702211T ATE446104T1 AT E446104 T1 ATE446104 T1 AT E446104T1 AT 02702211 T AT02702211 T AT 02702211T AT 02702211 T AT02702211 T AT 02702211T AT E446104 T1 ATE446104 T1 AT E446104T1
Authority
AT
Austria
Prior art keywords
hepatitis
atagen
interferon
recombinant super
antigen inhibitor
Prior art date
Application number
AT02702211T
Other languages
English (en)
Inventor
Guangwen Wei
Rongbing Guo
Renhuai Zhang
Original Assignee
Sichuan Biotechnology Res Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Biotechnology Res Ct filed Critical Sichuan Biotechnology Res Ct
Application granted granted Critical
Publication of ATE446104T1 publication Critical patent/ATE446104T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02702211T 2001-02-28 2002-02-28 Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor ATE446104T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB011043679A CN1245215C (zh) 2001-02-28 2001-02-28 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
PCT/CN2002/000128 WO2002080958A1 (fr) 2001-02-28 2002-02-28 Interferon supercompose de recombinaison utilise comme inhibiteur de l'antigene de surface et de l'antigene e de l'hepatite b

Publications (1)

Publication Number Publication Date
ATE446104T1 true ATE446104T1 (de) 2009-11-15

Family

ID=4653854

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02702211T ATE446104T1 (de) 2001-02-28 2002-02-28 Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor

Country Status (9)

Country Link
US (3) US7364724B2 (de)
EP (1) EP1371373B1 (de)
JP (1) JP4617058B2 (de)
CN (1) CN1245215C (de)
AT (1) ATE446104T1 (de)
AU (1) AU2003248419B2 (de)
CA (1) CA2439503A1 (de)
DE (1) DE60234085D1 (de)
WO (1) WO2002080958A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US7335496B2 (en) * 2003-06-05 2008-02-26 Ajinomoto Co., Inc. Method for producing target substance
KR20060130009A (ko) * 2003-08-28 2006-12-18 휴이양테크 (유에스에이), 인크. 변경된 공간 구조를 갖는 인터페론의 용도
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
PT1663110E (pt) * 2003-08-28 2014-03-13 Superlab Far East Ltd Utilizações de interferões com a estrutura espacial alterada
AU2011202683B2 (en) * 2003-08-28 2012-08-09 Superlab Far East Limited Uses of interferons with altered spatial structure
CN1740197B (zh) * 2004-08-26 2010-05-12 辉阳科技美国公司 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用
AU2006257286B2 (en) * 2005-03-09 2012-08-16 Superlab Far East Limited Uses of recombinant super-compound interferons
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
CN102101886A (zh) * 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
WO2013055811A1 (en) * 2011-10-12 2013-04-18 Hitachi Chemical Co., Ltd. Ex vivo methods of predicting responsiveness of a subject to interferon therapy
EP2583677A3 (de) 2011-10-21 2013-07-03 Abbvie Inc. Verfahren zur Behandlung von HCV mit wenigstens zwei direkt angreifenden viralen Mitteln, Ribavirin aber nicht Interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
TW201427681A (zh) 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
KR102230547B1 (ko) 2013-11-13 2021-03-22 수퍼랩 파 이스트 리미티드 종양에 대한 직접적 억제 효과를 갖는 인터페론을 결정하는 방법 및 그의 용도
US10877024B2 (en) 2015-05-12 2020-12-29 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN111658779A (zh) * 2020-06-22 2020-09-15 四川大学华西医院 治疗新型冠状病毒肺炎的联合用药物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
ATE18410T1 (de) 1981-12-07 1986-03-15 Hoffmann La Roche Kristallines human-leukocyten-interferon.
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4681930A (en) * 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5441734A (en) * 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
DE4329756A1 (de) 1993-09-03 1995-03-09 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von alpha-Interferon
EP0626448A3 (de) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
CA2232230C (en) 1995-10-13 2005-06-28 Ralph H. Lambalot Phosphopantetheinyl transferases and uses thereof
US5972331A (en) * 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US5874304A (en) * 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US6532437B1 (en) * 1996-10-23 2003-03-11 Cornell Research Foundation, Inc. Crystalline frap complex
CN1186120A (zh) 1996-12-24 1998-07-01 深圳科兴生物制品有限公司 在大肠杆菌中表达作为分泌的重组人干扰素α1b蛋白
AU1619699A (en) * 1997-12-05 1999-06-28 Human Genome Sciences, Inc. Synferon, a synthetic type i interferon
US6087478A (en) * 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
TR200002271T2 (tr) 1998-02-06 2000-11-21 Ilexus Pty Limited Fc alıcılarının üç boyutlu yapıları ve modelleri ve bunların kullanımı
CN1062565C (zh) 1998-06-29 2001-02-28 深圳九先生物工程有限公司 重组人α型复合干扰素及其制备方法和用途
KR100399156B1 (ko) 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US20020043262A1 (en) * 2000-08-22 2002-04-18 Alan Langford Spray device
US7544354B2 (en) * 2000-10-27 2009-06-09 Novartis Vaccines And Diagnostics Methods of protein purification and recovery
US7666995B2 (en) 2000-11-03 2010-02-23 Pestka Biomedical Laboratories Interferons, uses and compositions related thereto
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US6546074B1 (en) * 2001-03-27 2003-04-08 Astex Technology Limited Protein crystal structure and method for identifying protein modulators
CN1375502A (zh) 2001-10-25 2002-10-23 南京药科大学 聚乙二醇修饰重组人干扰素
US6807478B2 (en) * 2001-12-27 2004-10-19 Koninklijke Philips Electronics N.V. In-building navigation system
CN1176946C (zh) 2002-05-16 2004-11-24 中国人民解放军第二军医大学 一种新型α干扰素
CN1202861C (zh) 2003-07-18 2005-05-25 中国科学院微生物研究所 复合干扰素在治疗sars疾病中的用途
KR20060130009A (ko) 2003-08-28 2006-12-18 휴이양테크 (유에스에이), 인크. 변경된 공간 구조를 갖는 인터페론의 용도
WO2005067963A1 (en) 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
AU2006257286B2 (en) 2005-03-09 2012-08-16 Superlab Far East Limited Uses of recombinant super-compound interferons

Also Published As

Publication number Publication date
CA2439503A1 (en) 2002-10-17
EP1371373B1 (de) 2009-10-21
HK1061201A1 (en) 2004-09-10
US20080305080A1 (en) 2008-12-11
DE60234085D1 (de) 2009-12-03
US8114395B2 (en) 2012-02-14
US20110189128A1 (en) 2011-08-04
EP1371373A4 (de) 2005-05-04
WO2002080958A1 (fr) 2002-10-17
AU2003248419A1 (en) 2003-11-06
CN1245215C (zh) 2006-03-15
US7364724B2 (en) 2008-04-29
JP2005508848A (ja) 2005-04-07
CN1311035A (zh) 2001-09-05
US8425896B2 (en) 2013-04-23
JP4617058B2 (ja) 2011-01-19
US20040202641A1 (en) 2004-10-14
AU2003248419B2 (en) 2007-01-04
EP1371373A1 (de) 2003-12-17

Similar Documents

Publication Publication Date Title
ATE446104T1 (de) Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor
DK1476541T3 (da) Cytokin (zcytor17-ligand)
ES2523837T3 (es) Agentes de unión específica al factor de crecimiento de hepatocitos
NO20034396D0 (no) Rekombinante antistoff uttrykt sammen med GnTIII
DK1576112T3 (da) Cytokin-receptor zcytor17-multimerer
ATE263778T1 (de) Niedrigallergene proteinvarianten
EP1423136A4 (de) Polypeptid-konjugate mit verlängerten zirkulierenden halbwertszeiten
EP1499352A4 (de) Rekombinante anti-interleukin-9-antikörper
DK1406656T3 (da) Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer
HUP0402333A3 (en) Modified anti-tnf alpha antibody
ATE417275T1 (de) Puffern zur stabilizierung von hcv antigenen
IS7576A (is) And-mýelíntengd glýkóprótín (MAG) mótefni
CY1111750T1 (el) Νευροτροφικοι παραγοντες
CY2011020I2 (el) Νεα πεπτιδια ως αναστολεα πρωτεασης ns3-σερινης του ιου ηπατιτιδας c
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
LU92748I2 (fr) Virus de la diarrhée virale bovine atténué 2 (bvdv-2)
DE60138014D1 (de) Chimäre arterivirus-ähnliche partikel
DK1501936T3 (da) Familie af cytokin-proteiner
DE60115938D1 (de) Monoklonale antikörper gegen hepatitis b virus
EP1359932A4 (de) Tip39 polypeptide
EP1490396A4 (de) Immunogene hiv-peptide zur verwendung als reagentien und impfstoffe
EP1501869A4 (de) Phosphoryliertes histon h2b als apoptosemarker
FI4950U1 (fi) Keraaminen tiili
IT249638Y1 (it) Disposizione di proiettori di luce per l'illuminazione di dipinti.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties